Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shen Lu

Showing results (201-210 of 237) with videos related to

Pageof 24
Sort By:
Science (New York, N.Y.)|June 25, 2021
Structural basis for enhanced infectivity and immune evasion of SARS-CoV-2 variantsYongfei Cai, Jun Zhang, Tianshu Xiao, et al.
Biorxiv : the Preprint Server for Biology|April 21, 2021
Structural basis for enhanced infectivity and immune evasion of SARS-CoV-2 variantsYongfei Cai, Jun Zhang, Tianshu Xiao, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 29, 2020
A Phase Ib Study of Alpelisib or Buparlisib Combined with Tamoxifen Plus Goserelin in Premenopausal Women with HR-Positive HER2-Negative Advanced Breast CancerYen-Shen Lu, Keun Seok Lee, Tsu-Yi Chao, et al.
Therapeutic Advances in Medical Oncology|July 26, 2023
Oral paclitaxel and encequidar in patients with breast cancer: a pharmacokinetic, safety, and antitumor activity studyMing-Shen Dai, Ta-Chung Chao, Chang-Fang Chiu, et al.
The New England Journal of Medicine|June 6, 2019
Overall Survival with Ribociclib plus Endocrine Therapy in Breast CancerSeock-Ah Im, Yen-Shen Lu, Aditya Bardia, et al.
The New England Journal of Medicine|May 16, 2019
Alpelisib for <i>PIK3CA</i>-Mutated, Hormone Receptor-Positive Advanced Breast CancerFabrice André, Eva Ciruelos, Gabor Rubovszky, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 26, 2026
Durvalumab Plus Paclitaxel, with or without Capivasertib or Oleclumab, in Patients with Locally Advanced/Metastatic Triple-Negative Breast CancerPeter Schmid, Cynthia X Ma, Yeon Hee Park, et al.
Frontiers in Oncology|July 8, 2025
Part I: consensus statements and expert recommendations for <i>HER2</i>-negative early breast cancer in the Asia-Pacific region: diagnosis and risk assessmentSoo Chin Lee, Yeon Hee Park, Christian F Singer, et al.
Frontiers in Oncology|July 8, 2025
Part II: consensus statements and expert recommendations for BRCA-associated breast cancer in the Asia-Pacific region: clinical managementYeon Hee Park, Soo Chin Lee, Christian F Singer, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 9, 2026
Elevated phthalate exposure and metabolic susceptibility increased breast cancer risk: A 20-y follow-up study in TaiwanHui-Chi Chen, San-Lin You, Ching-Hung Lin, et al.
Pageof 24

Showing results (201-210 of 237) with videos related to

Sort By:
Pageof 24
Science (New York, N.Y.)|June 25, 2021
Structural basis for enhanced infectivity and immune evasion of SARS-CoV-2 variantsYongfei Cai, Jun Zhang, Tianshu Xiao, et al.
Biorxiv : the Preprint Server for Biology|April 21, 2021
Structural basis for enhanced infectivity and immune evasion of SARS-CoV-2 variantsYongfei Cai, Jun Zhang, Tianshu Xiao, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 29, 2020
A Phase Ib Study of Alpelisib or Buparlisib Combined with Tamoxifen Plus Goserelin in Premenopausal Women with HR-Positive HER2-Negative Advanced Breast CancerYen-Shen Lu, Keun Seok Lee, Tsu-Yi Chao, et al.
Therapeutic Advances in Medical Oncology|July 26, 2023
Oral paclitaxel and encequidar in patients with breast cancer: a pharmacokinetic, safety, and antitumor activity studyMing-Shen Dai, Ta-Chung Chao, Chang-Fang Chiu, et al.
The New England Journal of Medicine|June 6, 2019
Overall Survival with Ribociclib plus Endocrine Therapy in Breast CancerSeock-Ah Im, Yen-Shen Lu, Aditya Bardia, et al.
The New England Journal of Medicine|May 16, 2019
Alpelisib for <i>PIK3CA</i>-Mutated, Hormone Receptor-Positive Advanced Breast CancerFabrice André, Eva Ciruelos, Gabor Rubovszky, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 26, 2026
Durvalumab Plus Paclitaxel, with or without Capivasertib or Oleclumab, in Patients with Locally Advanced/Metastatic Triple-Negative Breast CancerPeter Schmid, Cynthia X Ma, Yeon Hee Park, et al.
Frontiers in Oncology|July 8, 2025
Part I: consensus statements and expert recommendations for <i>HER2</i>-negative early breast cancer in the Asia-Pacific region: diagnosis and risk assessmentSoo Chin Lee, Yeon Hee Park, Christian F Singer, et al.
Frontiers in Oncology|July 8, 2025
Part II: consensus statements and expert recommendations for BRCA-associated breast cancer in the Asia-Pacific region: clinical managementYeon Hee Park, Soo Chin Lee, Christian F Singer, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 9, 2026
Elevated phthalate exposure and metabolic susceptibility increased breast cancer risk: A 20-y follow-up study in TaiwanHui-Chi Chen, San-Lin You, Ching-Hung Lin, et al.
Pageof 24